Sanofi Entered into an Exclusive License Agreement with miRecule to Advance Antibody-RNA Conjugate for Facioscapulohumeral Muscular Dystrophy
Shots:
- miRecule to receive ~$30M up front incl. near-term milestones & is also eligible to receive ~$400M in development, regulatory, and commercial milestones to advance FSHD drug candidate along with royalties on global net sales of the approved product. Both companies collaborated on research activities through lead candidate selection
- Sanofi gets an exclusive license to IP rights globally for FSHD therapy (developed and commercialized by Sanofi) & will be responsible for IND enabling studies along with development and commercialization activities globally
- The collaboration combines miRecule’s anti-DUX4 RNA therapy with Sanofi’s NANOBODY technology for Ab-RNA conjugate (ARC) to treat FSHD by using NAVIgGator conjugation and formulation chemistry
Ref: Businesswire | Image: Estrella
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
